MicroVue™ C5a EIA

The MicroVue C5a Enzyme Immunoassay is for the measurement of C5a in human serum, plasma, and other biological or experimental samples.


Product Specifications

Citations 57
Specimen

Serum 10 μL, EDTA or Citrated Plasma 20 μL

LLOQ 0.05 ng/mL
ULOQ N/A
Assay Time 2.5 hours
Cross Reactivity

None

Ordering Information

For Research Use Only in the United States. Not for use in diagnostic procedures.
Catalog Number A021
Catalog Number (CE) A025
Size 96 wells/test
Price (USD) $725.00
Price (EURO) 640,00 €

Contact us

US Phone+1 (858) 552 1100
EU Phone+353 (91) 412 474
US Emailcontact-us@quidelortho.com
EU Emailcontact-emea@quidelortho.com

Specifications

Description

The MicroVue C5a Enzyme Immunoassay is for the measurement of C5a in human serum, plasma, and other biological or experimental samples.

Size 96 wells/test
Form

96 well plate with 12 eight-well strips in a resealable foil pouch

Specimen Serum 10 μL, EDTA or Citrated Plasma 20 μL
Limit of Detection (LOD) 0.01 ng/mL
Lower Limit of Quantitation (LLOQ) 0.05 ng/mL
Upper Limit of Quantitation (ULOQ) N/A
Intra Assay 3.5–3.9%
Inter Assay 7.1–13%
Standards 5
Controls 2
Sample Values

Serum 13.4–179.2 ng/mL, EDTA Plasma 0.37–74.3 ng/mL

Assay Time 2.5 hours
Cross Reactivity

None

Storage

Store the unopened kit at 2°C to 8°C. Refer to Product Insert for additional storage details.

Background

The MicroVue C5a Enzyme Immunoassay is a 96 well, direct-capture immunoassay for the measurement of C5a in human serum, plasma, and other biological or experimental samples. Under normal conditions, activation of the classical, alternative, or lectin complement pathways results in the formation of a C5 convertase multi-molecular enzyme capable of cleaving C5 to C5a and C5b. C5b is a key constituent of the Terminal Complement Complex and has a variety of functions in this role. C5a is a low molecular weight (approximately 9kD) protein fragment of 74 amino acids. C5a is rapidly metabolized by the serum enzyme carboxypeptidase to a more stable, less active, 73 amino acid form, C5a des-Arg. For convenience, both forms will be referred to as “C5a” for purposes of this documentation. The MicroVue C5a assay, which provides a rapid, highly specific and quantitative procedure for measuring C5a levels, is designed for investigations into the role or status of terminal complement pathway activation in numerous research settings, and for monitoring the generation of C5a in vivo or in vitro. As the most potent of the complement anaphylatoxins, C5a has a host of biologic functions including mast cell degranulation, chemotaxis, leukosequestration, as well as cellular activation via binding to the C5a Receptor (C5aR or CD88). Research has associated elevated levels of fluid phase and adsorbed C5a with hemo-incompatibility of some biomaterials, particularly in extracorporeal circuits. Research has also associated levels of C5a with pathogenesis of a variety of disease states including myocardial infarction, stroke, as well as vascular leak syndrome and associated kidney injury. The role of C5a in the pathogenesis of malaria20 and other infectious diseases, as well as sepsis, is likewise well documented.

Citations

Title Year Applications Sample Species Sample Sample Details

Pentraxin 3 recruits complement factor H to protect against oxidative stress-induced complement and inflammasome overactivation.

2016

ELISA

Human

ARPE-19 Cells

Complete kinetic follow-up of symptoms and complement parameters during a hereditary angioedema attack.

2017

ELISA

Human

Plasma

Hereditary Angioedema

Brain microvascular endothelial cells exhibit lower activation of the alternative complement pathway than glomerular microvascular endothelial cells.

2018

ELISA

Human

GMVEC cells, BMVEC cells

Measuring Circulating Complement Activation Products in Myeloperoxidase- and Proteinase 3-Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.

2019

ELISA

Human

Plasma

ANCA-AAV

Subvisible Particles in IVIg Formulations Activate Complement in Human Serum.

2020

ELISA

Human

Serum

IVIg formulations

Complement factor H contributes to mortality in humans and mice with bacterial meningitis.

2019

ELISA

Human

CSF

Bacterial meningitis

Complement Activation Profile of Patients With Primary Focal Segmental Glomerulosclerosis.

2020

ELISA

Human

Plasma

FSGS

Complement Activation Profile of Patients With Primary Focal Segmental Glomerulosclerosis.

2020

ELISA

Human

Serum

FSGS

Temporal changes in complement activation in haemodialysis patients with COVID-19 as a predictor of disease progression.

2020

ELISA

Human

Plasma

COVID-19

Complement activation and endothelial perturbation parallel COVID-19 severity and activity.

2020

ELISA

Human

Plasma

COVID-19

Alternative complement pathway activation in thrombotic microangiopathy associated with lupus nephritis.

2020

ELISA

Human

Serum

Lupus Nephritis, Thrombotic Microangiopathy

Alternative complement pathway activation in thrombotic microangiopathy associated with lupus nephritis.

2020

ELISA

Human

Urine

Lupus Nephritis, Thrombotic Microangiopathy

Complement levels at admission as a reflection of coronavirus disease 2019 (COVID-19) severity state.

2021

ELISA

Human

Serum

COVID-19

von Willebrand factor variants in C3 glomerulopathy: A Chinese cohort study.

2021

ELISA

Human

Plasma

C3G

von Willebrand factor variants in C3 glomerulopathy: A Chinese cohort study.

2021

ELISA

Human

Urine

C3G

Early Elevation of Complement Factor Ba Is a Predictive Biomarker for Transplant-Associated Thrombotic Microangiopathy

2021

ELISA

Human

Plasma

Thrombotic Microangiopathy - TA

Dendrimer end-terminal motif-dependent evasion of human complement and complement activation through IgM hitchhiking.

2021

ELISA

Human

Plasma

The Influence of an Elastase-Sensitive Complement C5 Variant on Lupus Nephritis and Its Flare.

2021

ELISA

Human

Plasma

Lupus Nephritis

Thromboinflammation Supports Complement Activation in Cancer Patients With COVID-19.

2021

ELISA

Human

Plasma

Cancer, COVID-19

Thromboinflammation Supports Complement Activation in Cancer Patients With COVID-19.

2021

ELISA

Human

Plasma

COVID-19

C5a and C5aR1 are key drivers of microvascular platelet aggregation in clinical entities spanning from aHUS to COVID-19.

2022

ELISA

Human

Plasma

aHUS

C5a and C5aR1 are key drivers of microvascular platelet aggregation in clinical entities spanning from aHUS to COVID-19.

2022

ELISA

Human

Plasma

COVID-19

Human Neutrophils Respond to Complement Activation and Inhibition in Microfluidic Devices.

2021

ELISA

Human

Serum

Persistently elevated complement alternative pathway biomarkers in COVID-19 correlate with hypoxemia and predict in-hospital mortality.

2022

ELISA

Human

Plasma

COVID-19

Persistently elevated complement alternative pathway biomarkers in COVID-19 correlate with hypoxemia and predict in-hospital mortality.

2022

ELISA

Human

Serum

COVID-19

High plasma C5a and C5b-9 levels during quiescent phases are associated to severe antiphospholipid syndrome subsets.

2022

ELISA

Human

Plasma

Antiphospholipid syndrome

Complement Activation in Patients With Heat-Related Illnesses: Soluble CD59 Is a Novel Biomarker Indicating Severity of Heat-Related Illnesses.

2022

ELISA

Human

Plasma

Heat-related illnesses

Circulating immune-complexes and complement activation through the classical pathway in myeloperoxidase-ANCA-associated glomerulonephritis.

2022

ELISA

Human

Serum

Myeloperoxidase-ANCA-associated glomerulonephritis

Comparison of Complement Pathway Activation in Autoimmune Glomerulonephritis.

2022

ELISA

Human

Urine

AAV, FSGS, IgAN, MN, and LN

Plasma C4 level was associated with mortality, cardiovascular and cerebrovascular complications in hemodialysis patients.

2022

ELISA

Human

Plasma

Hemodialysis

CipA mediates complement resistance of Acinetobacter baumannii by formation of a factor I-dependent quadripartite assemblage.

2022

ELISA

Human

Serum

CipA

Serum and plasma levels of Ba, but not those of soluble C5b-9, might be affected by renal function in chronic kidney disease patients.

2023

ELISA

Human

Plasma, Serum

Glomerulonephritis

Complement activation in severely ill patients with sepsis: no relationship with inflammation and disease severity.

2023

ELISA

Human

Plasma

Sepsis

Linkage specificity and role of properdin in activation of the alternative complement pathway by fungal glycans.

2011

ELISA

Human

Serum

Human pentraxin 3 binds to the complement regulator c4b-binding protein

2011

ELISA

Human

Fibroblasts

A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of function

2012

ELISA

Human

Serum

GEnCs and HUVEC exposed

Complement activation in pediatric patients with recurrent acute otitis media

2013

ELISA

Human

Ear Fluid (MEE)

Complement activation in pediatric patients with recurrent acute otitis media

2013

ELISA

Human

Serum

Genetic variation and cerebrospinal fluid levels of mannose binding lectin in pneumococcal meningitis patients.

2013

ELISA

Human

CSF

Clinicopathological characteristics and outcomes of Chinese patients with scanty immune deposits lupus nephritis: a large cohort study from a single center

2014

ELISA

Human

Plasma

Lupus Nephritis

Associations between abnormal rod-mediated dark adaptation and health and functioning in older adults with normal macular health

2014

ELISA

Human

Plasma

Defining the complement biomarker profile of C3 glomerulopathy

2014

ELISA

Human

Plasma

C3G

The Local Complement Activation on Vascular Bed of Patients with Systemic Sclerosis: A Hypothesis-Generating Study

2015

ELISA

Human

Plasma

Cerebrospinal fluid inflammatory markers in patients with Listeria monocytogenes meningitis

2014

ELISA

Human

CSF

Listeria meningitis

Plasma complement factor H is associated with disease activity of patients with ANCA-associated vasculitis

2015

ELISA

Human

Plasma

Genetic engineering strategies to prevent the effects of antibody and complement on xenogeneic chondrocytes

2015

ELISA

Human

Serum

Porcine articular chondrocytes

Neutrophil activation during attacks in patients with hereditary angioedema due to C1-inhibitor deficiency

2015

ELISA

Human

Plasma

Tumour exosomes display differential mechanical and complement activation properties dependent on malignant state: implications in endothelial leakiness

2015

ELISA

Human

Serum

Platelet-borne complement proteins and their role in platelet–bacteria interactions

2016

ELISA

Human

Plasma

Activation of Human Complement System by Dextran-Coated Iron Oxide Nanoparticles Is Not Affected by Dextran/Fe Ratio, Hydroxyl Modifications, and Crosslinking.

2016

ELISA

Human

Serum

Imprime PGG-Mediated Anti-Cancer Immune Activation Requires Immune Complex Formation

2016

ELISA

Human

Plasma

Imprime yeast treated

VEGF regulates local inhibitory complement proteins in the eye and kidney

2016

ELISA

Human

Aqueous humour

Brain injury with systemic inflammation in newborns with congenital heart disease undergoing heart surgery

2017

ELISA

Human

Serum

Trauma, newborn brain

Assessing single-stranded oligonucleotide drug-induced effects in vitro reveals key risk factors for thrombocytopenia

2017

ELISA

Human

Plasma

Platelets are activated in ANCA-associated vasculitis via thrombin-PARs pathway and can activate the alternative complement pathway

2017

ELISA

Human

Plasma

ANCA-AAV

rIgG1 Fc Hexamer Inhibits Antibody-Mediated Autoimmune Disease via Effects on Complement and FcγRs

2018

ELISA

Human

Serum

Fc activation

A Prospective Study on Complement Activation Distinguishes Focal Segmental Glomerulosclerosis from Minimal Change Disease

2024

ELISA

Human

Urine

FSGS, MCD